TRV GP V, LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 7, 2026), TRV GP V, LLC reported 3 stock positions worth $401.0 million. Its top holding was Rapport Therapeutics (RAPP) at 55.7% of the portfolio, followed by Septerna (SEPN, 37.2%) and Maze Therapeutics (MAZE, 7.1%). Its holdings were unchanged from Q4 2025.

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001990717
Portfolio Value
$401.0M (Q1 2026)
SEC Filing
0001193125-26-212010 ↗ filed May 7, 2026

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q4 2024: $294.0M Q4 2024 Q1 2025: $125.1M Q1 2025 Q2 2025: $165.7M Q2 2025 Q3 2025: $353.5M Q3 2025 Q4 2025: $429.2M Q4 2025 Q1 2026: $401.0M $401.0M Q1 2026 Q2 2026: $498.2M Q2 2026

Holdings 3 stocks · $401.0M
RAPP Rapport Therapeutics Inc. 55.68% 7,135,233 $223.3M No change
SEPN Septerna Inc. 37.25% 6,215,591 $149.4M No change
MAZE Maze Therapeutics Inc. 7.08% 950,800 $28.4M No change

Portfolio Sells Q4 2025 → Q1 2026
None this quarter.

Portfolio Buys Q4 2025 → Q1 2026
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$498.2MRAPP, SEPN, MAZE
Q1 2026 3$401.0MRAPP, SEPN, MAZE
Q4 2025 3$429.2MRAPP, SEPN, MAZE
Q3 2025 3$353.5MRAPP, SEPN, MAZE
Q2 2025 4$165.7MRAPP, SEPN, MAZE, CRGX
Q1 2025 4$125.1MRAPP, SEPN, MAZE, CRGX
Q4 2024 3$294.0MSEPN, RAPP, CRGX